First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund
US ˙ ARCA ˙ US33733E2037

SecurityFBT / First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund
InstitutionUbs Ag
Latest Disclosed Ownership725,782 shares
Latest Disclosed Value $ 66,612,000
Ubs Ag reports 5.55% increase in ownership of FBT / First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund

On November 12, 2014 - Ubs Ag filed a 13F-HR form disclosing ownership of 725,782 shares of First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund (US:FBT) valued at $66,612,272 USD as of September 30, 2014. The entity filed a previous 13F-HR on August 14, 2014 disclosing 687,611 shares of First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund. This represents a change in shares of 5.55% during the quarter. The current value of the position is $160,506,689 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2014-11-12 2014-09-30 13F FIRST TR EXCHANGE TRADED FD NY ARCA BIOTECH 33733E203 725,782 38,171 5.55 66,612 17.67 0.0491
2014-08-14 2014-06-30 13F FIRST TR EXCHANGE TRADED FD NY ARCA BIOTECH 33733E203 687,611 109,329 18.91 56,611 27.65 0.0443
2014-05-16 2014-03-31 13F/A-1 FIRST TR EXCHANGE TRADED FD NY ARCA BIOTECH 33733E203 578,282 20,741 3.72 44,348 14.98 0.0394
2014-05-15 2014-03-31 13F FIRST TR EXCHANGE TRADED FD NY ARCA BIOTECH 33733E203 578,282 44,348
2014-05-21 2013-12-31 13F/A-1 FIRST TR EXCHANGE TRADED FD NY ARCA BIOTECH 33733E203 557,541 91,157 19.55 38,571 27.63 0.0361
2014-02-14 2013-12-31 13F FIRST TR EXCHANGE TRADED FD NY ARCA BIOTECH 33733E203 557,541 38,571
2013-11-13 2013-09-30 13F FIRST TR EXCHANGE TRADED FD NY ARCA BIOTECH 33733E203 466,384 115,919 33.08 30,222 48.19 0.0309
2013-08-14 2013-06-30 13F FIRST TR EXCHANGE TRADED FD NY ARCA BIOTECH 33733E203 350,465 350,465 20,394 0.0242
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.